Cancer News and Research

Latest Cancer News and Research

Cubist second quarter total net revenues increase 30% to $230.6M

Cubist Pharmaceuticals, Inc. today announced results for the second quarter ended June 30, 2012.

20 Jul 2012

GUMC, MedStar GUH launch Huntington Disease Care, Education and Research Center

Georgetown University Medical Center in collaboration with MedStar Georgetown University Hospital announce the launch of the Huntington Disease Care, Education and Research Center.

20 Jul 2012

BioAlliance Pharma, Vestiq enter license agreement for Oravig to treat oropharyngeal candidiasis

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces it has signed a binding term sheet with Vestiq for the commercialization rights in the United States of Oravig (known as Loramyc in Europe) for the treatment of oropharyngeal candidiasis in adults.

20 Jul 2012

Actinium completes Actimab-A Phase I/II study on Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City.

20 Jul 2012

Longer looks: Physicians and assisted suicide; Avoid getting sick in July

Peggy Sutherland was ready to die. The morphine oozing from a pump in her spine was no match for the pain of lung cancer, which had evaded treatment and invaded her ribs. … Sutherland, 68, decided to use Oregon's "Death With Dignity Act," which allows terminally-ill residents to end their lives after a 15-day requisite waiting period by self-administering a lethal prescription drug. ... But not all doctors are on board with the law.

20 Jul 2012

Viral Genetics initiates Phase 1 trial of MDT compounds for ovarian cancer

The first patient has now been enrolled into the Phase 1 clinical trial sponsored by Viral Genetics' and supported by a donation from Scott and White Foundation. The trial will study Metabolic Disruption Technology (MDT) compounds in combination with an existing cancer therapy to treat drug-resistant ovarian cancer.

20 Jul 2012

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012

Patients, partners affected by colorectal cancer course

Partners of individuals with colorectal cancer, as well as the patients themselves, are at risk for psychologic morbidity according to the type of treatment given, show Portuguese study results.

19 Jul 2012

NeoGenomics second quarter 2012 revenue increases 49% to $15.6 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the second quarter 2012.

19 Jul 2012

Researchers discover potential drug targets that might reduce ventilator-induced lung inflammation

When hospital patients need assistance breathing and are placed on a mechanical ventilator for days at a time, their lungs react to the pressure generated by the ventilator with an out-of-control immune response that can lead to excessive inflammation, new research suggests.

19 Jul 2012

Bryologs more potent than prostratin in treating HIV

Thanks to antiretrovirals, an AIDS diagnosis hasn't been a death sentence for nearly two decades. But highly active antiretroviral therapy, or HAART, is also not a cure.

19 Jul 2012

Huddersfield scientist receives Pain Relief Foundation grant for research into BH4 pathway

SOME victims of serious illness experience much less pain than other sufferers, thanks to a natural biochemical variation in the cells of their bodies. Now a scientist at the University of Huddersfield has been awarded research funding that will aid his project to learn more about this variation and therefore develop treatments that could lead to the relief of pain for all patients, with much less dependence on drugs that can have distressing side effects.

19 Jul 2012

Adolescents and young adult cancer patients more likely to report unmet need

A cancer diagnosis for adolescents and young adults can be especially challenging, and new research shows the social, psychological and informational support these patients need might be going unmet.

19 Jul 2012

New research sheds light on pluripotency

New research at the Hebrew University of Jerusalem sheds light on pluripotency-the ability of embryonic stem cells to renew themselves indefinitely and to differentiate into all types of mature cells.

19 Jul 2012

U.S. News names Dana-Farber/ BWH Cancer Center among 2012 America's Best Hospitals

U.S. News & World Report's Best Hospitals guide has ranked Dana-Farber/Brigham and Women's Cancer Center the top cancer center in New England and fifth overall in the country.

19 Jul 2012

Alcohol and marijuana use predict hookah initiation, frequency

Nearly a quarter of college women try smoking tobacco with a hookah, or water pipe, for the first time during their freshman year, according to new research from The Miriam Hospital's Center for Behavioral and Preventive Medicine.

19 Jul 2012

Inhibiting STAT3 might unleash an effective anti-lymphoma immune response

Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.

19 Jul 2012

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

AMAG Pharmaceuticals, Inc. today reported preliminary results from the second phase III study from its global registrational program for Feraheme (ferumoxytol) in patients with iron deficiency anemia (IDA) regardless of the underlying cause.

19 Jul 2012

Book details minimum recommended guidelines for radiation oncology practices

The American Society for Radiation Oncology (ASTRO) is proud to announce the publication of Safety is No Accident: A Framework for Quality Radiation Oncology and Care, a comprehensive book detailing minimum recommended guidelines for radiation oncology practices.

19 Jul 2012

New UC M program to test comprehensive care physician model

Patients who are frequently hospitalized account for a disproportionate amount of health care spending in the United States. Working with a $6.1 million grant, a new University of Chicago Medicine program will test whether an updated version of the traditional general practitioner can reduce spending while also improving care for these patients.

19 Jul 2012